Switzerland· 47063035
Rifater, comprimés enrobés
A rifampicin, pyrazinamide and isoniazid product containing rifampicinum, isoniazidum, pyrazinamidum, registered in Switzerland by Sanofi-Aventis (Suisse) SA and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 6 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Rifampicin, pyrazinamide and isoniazid is registered in 6 of 19 countries.
Countries holding a registration under ATC J04AM05 (rifampicin, pyrazinamide and isoniazid), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 4 of them publish a price we can compare per daily dose
Rifampicin, pyrazinamide and isoniazid · ATC J04AM05
6 / 19 countries
- Czechiaprice
- Finlandprice
- Ireland
- Norwayprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Swissmedic (Switzerland)- Active substance
- rifampicinum, isoniazidum, pyrazinamidum
- Manufacturer
- Sanofi-Aventis (Suisse) SA
- Country
- Switzerland (CH)
- ATC code
- J04AM05
- ATC class
- Rifampicin, pyrazinamide and isoniazid
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768047063035360 StkCHF 38.25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
61 interactions on record for rifampicin, pyrazinamide and isoniazid.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rifampicin, pyrazinamide and isoniazid · interactions on record
61 records
61 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Rifampicin, pyrazinamide and isoniazid in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomRifater tabletsDrugsrus Ltd
- NorwayRifaterSanofi-aventis
- FinlandRimcureSandoz A/S
- FranceRIFATER, comprimé enrobéSANOFI WINTHROP INDUSTRIE
- IrelandRifater 50 mg/300 mg/120 mg TabletsSanofi-Aventis Ireland Limited T/A SANOFI
- CzechiaRIFAMPICIN 75MG + ISONIAZID 50MG + PYRAZINAMIDE 150MG
- SwedenRimcure 150 mg/75 mg/400 mg Filmdragerad tablettSandoz A/S
- SpainRIFATER COMPRIMIDOS RECUBIERTOSSanofi Aventis S.A.
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- Spain · Rifater
- France · Rifater
- United Kingdom (Northern Ireland) · Rifater
- Ireland · Rifater
- Italy · Rifater
- Norway · Rimcure
- Portugal · Rifater
- Sweden · Rimcure
- Slovenia · Rifater
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/59356e98-4485-4ace-9677-e4735aec03a8 GET /v1/drugs/59356e98-4485-4ace-9677-e4735aec03a8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "rifampicinum 120 mg + isoniazidum 50 mg + pyrazinamidum 300 mg",
"valid_from": "1987-03-15",
"limitations": null,
"galenic_form": "Drag 50 mg",
"therapeutic_area": null,
"sl_inclusion_date": "1987-03-15",
"self_retention_pct": 10
}See everything about rifampicin, pyrazinamide and isoniazid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.